In a new update issued today (July 15), the Medicines and Healthcare products Regulatory Agency (MHRA) confirmed it is stepping up its safety warnings for all products containing botulinum toxin type ...

Topline data from the phase 3 E-BEOND and C-BEOND trials show a significant reduction in monthly migraine days at 24 weeks, demonstrating efficacy across the full migraine spectrum.

CKD Bio marked the first anniversary of its proprietary botulinum toxin Tmbus Inj. by hosting a symposium to share clinical ...

Daewoong Pharmaceutical said Monday that cumulative sales of its proprietary botulinum toxin product Nabota surpassed 1 ...

Dysport® achieved statistically significant topline Phase III results, meeting primary endpoints in both episodic (E-BEOND) ...

BETWEEN social media, work calls and selfies, these days we’re constantly looking at ourselves on screen. Meanwhile, celebs ...

The company claims that Dysport is now the first botulinum toxin therapy to demonstrate efficacy in episodic migraine.

Daewoong Pharma's in-house botulinum toxin product Nabota has surpassed 1 trillion won ($665 million) in cumulative sales, ...

A tube thinner and shorter than a thumb, holding what looks like little more than a drop or two of clear liquid, sat locked ...

World Plastic Surgery Day is observed every year on July 15. The day highlights the important role of plastic surgeons in ...

Medytox announced on June 30 that its affiliate, NewMeco, has received product approval for the botulinum toxin product ...

Whether a person lives in Hawaii, the Mojave Desert or in Oklahoma, skin care is important, and proper care involves sun protection. Aracelly Walden is an esthetician who travels back and forth to ...